Breast cancer is classified into various subtypes according to histopathology and at the molecular level, considering the expression of cell surface markers such as the estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (ERBB2), among others, whose expression help to predict possible treatment responses [3,4,5]. This evidence concerns the gene ERBB2 and breast cancer.